Sanofi News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

28.10.22	Press Release: Continued strong growth in Q3 with key regulatory milestones achieved (GlobeNewswire)
11.10.22	Regeneron Reports Positive Results From Dupixent Phase 3 Trial In 1 To 11 Yrs With EoE (RTTNews)
11.10.22	Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old (GlobeNewswire)
06.10.22	Provention Bio Announces Collaboration With Sanofi To Expand Commercial Footprint For Teplizumab (RTTNews)
29.09.22	Regeneron : FDA Approves Dupixent For Prurigo Nodularis Treatment (RTTNews)
29.09.22	Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis (GlobeNewswire)
28.09.22	Press Release: Availability of the Q3 2022 Memorandum for modelling purposes (GlobeNewswire)
16.09.22	AstraZeneca: CHMP Recommends Beyfortus For EU Approval - Quick Facts (RTTNews)
16.09.22	Press Release: CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infants (GlobeNewswire)
08.09.22	Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis (GlobeNewswire)
05.09.22	Sanofi: Dupixent Data Show Sustained Improvement For Up To 2 Yrs In 6-11 Years With Asthma (RTTNews)
05.09.22	Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma (GlobeNewswire)
05.09.22	Press Release: Evolution of the Board of Directors (GlobeNewswire)
31.08.22	Press Release: XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations) (GlobeNewswire)
30.08.22	Sanofi - Aventis : FDA Grants Priority Review To Efanesoctocog Alfa For Rare Bleeding Disorder (RTTNews)
30.08.22	Press Release: FDA grants priority review to efanesoctocog alfa for people with hemophilia A (GlobeNewswire)
26.08.22	Sanofi's Higher Dose Flu Vaccines Preferentially Recommended By CDC ACIP For Adults 65+ (RTTNews)
17.08.22	Pre-market Movers: HIL, BBBY, JCSE, SAVA, MX… (RTTNews)
17.08.22	Sanofi Discontinues Studies Of Amcenestrant In Breast Cancer (RTTNews)
17.08.22	Press Release: Sanofi provides update on amcenestrant clinical development program (GlobeNewswire)
11.08.22	Pre-market Movers: SWX, GWAV, CSSE, NVTA, SONO… (RTTNews)
04.08.22	Press Release: Sanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology medicines and expand presence in China (GlobeNewswire)
28.07.22	Press Release: Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease (GlobeNewswire)
21.07.22	Innate Pharma: Sanofi To Progress IPH6401/SAR'514 Into Development; Triggers Milestone Payment (RTTNews)
14.07.22	Regeneron: Phase 3 Trial Of Dupixent In Children With Eosinophilic Esophagitis Meets Main Goal (RTTNews)
14.07.22	Press Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis (GlobeNewswire)
10.07.22	Press Release: Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis (GlobeNewswire)
10.07.22	Press Release: Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis (GlobeNewswire)
04.07.22	Sanofi Global Health Launches Impact Brand For 30 Medicines In Low-income Countries (RTTNews)
04.07.22	Sanofi Global Health launches nonprofit Impact® brand for 30 medicines in low-income countries (GlobeNewswire)
01.07.22	Regeneron Completes Acquiring Sanofi's Stake In Libtayo (RTTNews)
30.06.22	Sanofi's Late-stage Studies Of Tolebrutinib In Multiple Sclerosis And Myasthenia Gravis Put On Hold (RTTNews)
28.06.22	Press Release: Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease (GlobeNewswire)
28.06.22	Press Release: Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD (GlobeNewswire)
24.06.22	Sanofi-GSK Reports Positive Data From COVID-19 Beta-containing Vaccine Trial (RTTNews)
24.06.22	Availability of the Q2 2022 Memorandum for modelling purposes (GlobeNewswire)
24.06.22	Press Release: Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine (GlobeNewswire)
13.06.22	Press Release: Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron (GlobeNewswire)
08.06.22	Sanofi launches its first Digital Accelerator fueled by new talent and focused on growth (GlobeNewswire)
08.06.22	Sanofi : FDA Approves Dupixent For Young Children With Moderate-to-severe Atopic Dermatitis (RTTNews)
07.06.22	Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis (GlobeNewswire)
07.06.22	Sanofi launches 2022 global Employee Stock Purchase Plan for 86.000 people (GlobeNewswire)
03.06.22	Immunocore Inks Clinical Trial Collaboration With Sanofi For Metastatic Skin Cancers (RTTNews)
02.06.22	Regeneron To Acquire Global Rights To Libtayo From Sanofi For $900 Mln, Plus Royalties (RTTNews)
02.06.22	Press Release: Sanofi grants Regeneron worldwide exclusive license rights to Libtayo® (cemiplimab) (GlobeNewswire)
01.06.22	Sanofi: FDA Grants Efanesoctocog Alfa Breakthrough Therapy Designation For Hemophilia A (RTTNews)
01.06.22	Press Release: FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A (GlobeNewswire)
31.05.22	Regeneron : FDA Accepts Dupixent For Priority Review In Adults With Prurigo Nodularis (RTTNews)
31.05.22	Press Release: FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis (GlobeNewswire)
30.05.22	Press Release: Update on Cialis® Rx-to-OTC Switch Actual Use Trial (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Lonza Grp	537.00	1.13 %	K V
Roche Hldg G	253.30	0.76 %	K V
Nestle	76.22	0.50 %	K V
Sonova Hldg	306.10	0.49 %	K V
Givaudan	3’896.00	0.33 %	K V
Holcim	88.08	-0.38 %	K V
UBS Group	27.64	-0.43 %	K V
Sika	227.50	-0.48 %	K V
ABB	49.11	-0.87 %	K V
Logitech Intl	70.54	-2.00 %	K V

mehr

09:54		Novartis-Aktie stabil: EU-Zulassung für Kisqali - Funktion des Schweizer Länderpräsidenten gestrichen
09:28		Aufschläge in Frankfurt: SDAX legt zum Start zu
09:28		Handel in Frankfurt: LUS-DAX sackt zum Handelsstart ab
09:28		Freundlicher Handel: SPI zum Start im Aufwind
09:28		Schwacher Wochentag in Frankfurt: DAX verliert zum Start des Mittwochshandels
09:28		FTSE 100 aktuell: FTSE 100 steigt zum Start des Mittwochshandels
09:28		Schwache Performance in Frankfurt: TecDAX zum Start des Mittwochshandels schwächer
09:28		Euro STOXX 50 aktuell: Euro STOXX 50 notiert zum Start im Minus

09:54

Novartis-Aktie stabil: EU-Zulassung für Kisqali - Funktion des Schweizer Länderpräsidenten gestrichen

09:28

Aufschläge in Frankfurt: SDAX legt zum Start zu

09:28

Handel in Frankfurt: LUS-DAX sackt zum Handelsstart ab

09:28

Freundlicher Handel: SPI zum Start im Aufwind

09:28

Schwacher Wochentag in Frankfurt: DAX verliert zum Start des Mittwochshandels

09:28

FTSE 100 aktuell: FTSE 100 steigt zum Start des Mittwochshandels